Drugs / HER-2/neu Intracellular Domain Protein
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT01922921 | Feb 2014 → Oct 2019 | HER2 positive breast carcinoma | University of Washington | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HER-2/neu Intracellular Domain Protein | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01922921 ↗ |
| Action | Deplete | “Vaccines made from HER2 intracellular domain (ICD) peptide may help the body build an effective immune response to kill tumor cells that express HER2.” NCT01922921 ↗ |
| Modality | Vaccine | “HER2 ICD peptide-based vaccine” NCT01922921 ↗ |